Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pasireotide
Drug ID BADD_D01684
Description Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Indications and Usage For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
Marketing Status Not Available
ATC Code H01CB05
DrugBank ID DB06663
KEGG ID D10147
MeSH ID C517782
PubChem ID 9941444
TTD Drug ID D0TV0C
NDC Product Code 0078-0634; 71161-126; 0078-0643; 55292-143; 71161-130; 55292-142; 55292-139; 0078-0642; 0078-0741; 55292-141; 55292-132; 0078-0633; 0078-0748; 55292-140; 55292-131; 71161-129; 55292-133; 0078-0635; 0078-0641; 71161-127; 71161-128
Synonyms pasireotide | cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-d-tryptophyl-L-lysyl-4-o-benzyl-L-tyrosyl-L-phenylalanyl-) | SOM-230 | SOM 230 | SOM230
Chemical Information
Molecular Formula C58H66N10O9
CAS Registry Number 396091-73-9
SMILES C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4 )OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dry mouth07.06.01.0020.011762%
Dry skin23.03.03.0010.003921%
Dysgeusia17.02.07.003; 07.14.03.0010.003921%
Dyspnoea02.01.03.002; 22.02.01.004--
Eating disorder19.09.01.008; 14.03.01.0080.003921%Not Available
Electrocardiogram QT prolonged13.14.05.0040.003921%
Erythema23.03.06.001--Not Available
Eyelid ptosis17.17.02.004; 06.05.01.0020.003921%Not Available
Fatigue08.01.01.0020.047046%
Frequent bowel movements07.02.04.0020.003921%Not Available
Gamma-glutamyltransferase increased13.03.01.0110.003921%
Gastrointestinal disorder07.11.01.0010.005881%Not Available
Gastrointestinal pain07.01.05.005--
Glycosylated haemoglobin increased13.02.02.0050.007841%Not Available
Haematoma24.07.01.001--
Haemoglobin13.01.05.018--Not Available
Headache17.14.01.0010.023523%
Hepatic steatosis14.08.04.005; 09.01.07.0030.011762%Not Available
Hepatitis09.01.07.0040.003921%Not Available
Hepatomegaly09.01.05.0010.003921%Not Available
Hyperadrenocorticism24.08.02.005; 14.11.01.009; 05.01.01.0030.003921%Not Available
Hypercholesterolaemia14.08.01.0010.007841%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.078411%
Hyperhidrosis23.02.03.004; 08.01.03.0280.005881%
Hyperphagia19.09.01.005; 14.03.01.007; 07.01.06.0180.005881%Not Available
Hypertension24.08.02.0010.009801%
Hypertriglyceridaemia14.08.02.0010.003921%
Hypoglycaemia05.06.03.001; 14.06.03.0010.019603%
Hypokalaemia14.05.03.0020.005881%
Hypopituitarism05.03.02.001--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages